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Abstract
Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized.
Most identified common susceptibility variants lie in non-protein-coding sequences. We
hypothesized that variants in the 3′ untranslated region at putative microRNA (miRNA) binding
sites represent functional targets that influence EOC susceptibility. Here, we evaluate the
association between 767 miRNA binding site single nucleotide polymorphisms (miRSNPs) and
EOC risk in 18,174 EOC cases and 26,134 controls from 43 studies genotyped through the
Collaborative Oncological Gene-environment Study. We identify several miRSNPs associated
with invasive serous EOC risk (OR=1.12, P=10−8) mapping to an inversion polymorphism at
17q21.31. Additional genotyping of non-miRSNPs at 17q21.31 reveals stronger signals outside
the inversion (P=10−10). Variation at 17q21.31 associates with neurological diseases, and our
collaboration is the first to report an association with EOC susceptibility. An integrated molecular
analysis in this region provides evidence for ARHGAP27 and PLEKHM1 as candidate EOC
susceptibility genes.
Genome wide association studies (GWAS) have identified hundreds of genetic variants
conferring low penetrance susceptibility to cancer1. More than 90% of these variants lie in
non protein-encoding sequences including non-coding RNAs and regions containing
regulatory elements (i.e. enhancers, promoters, untranslated regions (UTRs))1. The
emerging hypothesis is that common variants within non-coding regulatory regions
influence expression of target genes, thereby conferring disease susceptibility1.
MicroRNAs (miRNAs) are short non-coding RNAs that regulate gene expression post-
transcriptionally by binding primarily to the 3′ UTR of target messenger RNA (mRNA),
causing translational inhibition and/or mRNA degradation2-4. MiRNAs have been shown to
play a key role in the development of epithelial ovarian cancer (EOC) 2. We 5,6 and others 7
have found evidence that various miRNA-related single nucleotide polymorphisms
(miRSNPs) are associated with EOC risk, suggesting they may be key disruptors of gene
function and contributors to disease susceptibility 8,9. However, studies of miRSNPs that
affect miRNA-mRNA binding have been restricted by small sample sizes and therefore have
limited statistical power to identify associations at genome wide levels of significance7-9.
Larger-scale studies and more systematic approaches are warranted to fully evaluate the role
of miRSNPs and their contribution to disease susceptibility.
Here, we use the in silico algorithms, TargetScan 10,11 and Pictar 12,13 to predict
miRNA:mRNA binding regions involving genes and miRNAs relevant to EOC, and align
identified regions with SNPs in the dbSNP database (Methods). We then genotype 1,003
miRSNPs (or tagging SNPs with r2>0.80) in 18,174 EOC cases and 26,134 controls from 43
studies from the Ovarian Cancer Association Consortium (OCAC) (Supplementary Table
S1). Genotyping was performed on a custom Illumina Infinium iSelect array designed as
part of the Collaborative Oncological Gene-environment Study (COGS), an international
effort that evaluated 211,155 SNPs and their association with ovarian, breast, and prostate
cancer risk. Our investigation uncovers 17q21.31 as a new susceptibility locus for EOC, and
we provide insights into candidate genes and possible functional mechanisms underlying
disease development at this locus.
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Association analyses
Seven hundred and sixty-seven of the 1,003 miRSNPs passed genotype quality control (QC)
and were evaluated for association with invasive EOC risk; most of the miRSNPs that failed
QC were monomorphic (see Methods). Primary analysis of 14,533 invasive EOC cases and
23,491 controls of European ancestry revealed four strongly correlated SNPs (r2=0.99;
rs1052587, rs17574361, rs4640231, and rs916793) that mapped to 17q21.31 and were
associated with increased risk (per allele odds ratio (OR) = 1.10, 95% CI 1.06-1.13) at a
genome-wide level of significance (10−7); no other miRSNPs had associations stronger than
P<10−4 (Supplementary Fig. S1). The most significant association was for rs1052587
(P=1.9×10−7), and effects varied by histological subtype, with the strongest effect observed
for invasive serous EOC cases (OR=1.12, P=4.6×10−8) (Table 1). No heterogeneity in ORs
was observed across study sites (Supplementary Fig. S2).
Rs1052587, rs17574361, and rs4640231 reside in the 3′UTR of microtubule-associated
protein tau (MAPT), KAT8 regulatory NSL complex subunit 1 (KANSL1/KIAA1267), and
corticotrophin releasing hormone receptor 1 (CRHR1) genes, at putative binding sites for
miR-34a, miR-130a, and miR-34c, respectively. The fourth SNP, rs916793, is perfectly
correlated with rs4640231 and lies in a non-coding RNA, MAPT-antisense 1. 17q21.31
contains a ∼900kb inversion polymorphism14 (ch 17: 43,624,578-44,525,051 MB, human
genome build 37), and all three miRSNPs and the tagSNP are located within the inversion
(Fig. 1).
Chromosomes with the non-inverted or inverted segments of 17q21.31, respectively known
as haplotype 1 (H1) and haplotype 2 (H2), represent two distinct lineages that diverged ∼3
million years ago and have not undergone any recombination event 14. The four
susceptibility alleles identified here reside on the H2 haplotype that is reported to be rare in
Africans and East Asians, but is common (frequency >20%) and exhibits strong linkage
disequilibrium (LD) among Europeans 14, consistent with our findings. The H2 haplotype
has a frequency of 22% among European women in our primary analysis (Table 1) but only
3.2% and 0.3% among Africans (151 invasive cases, 200 controls) and Asians (716 invasive
cases, 1573 controls), respectively.
To increase genomic coverage at this locus, we evaluated an additional 142 non-miRSNPs at
17q21.31 that were also genotyped as part of COGS in the same series of OCAC cases and
controls. We also imputed genotypes using data from the 1000 Genomes Project15. These
approaches identified a second cluster of strongly correlated SNPs (r2>0.90) in a distinct
region proximal to the inversion (centered at chromosome 17: 43.5 MB, human genome
build 37) that was more significantly associated with the risk of all invasive EOCs (P= 10−9)
and invasive serous EOC specifically (P= 10−10) than the cluster of identified miRSNPs
(Fig. 1). Association results and annotation for SNPs in this second cluster are shown in
Supplementary Table S2; this cluster includes three directly genotyped SNPs (rs2077606,
rs17631303, and rs12942666), with the strongest association observed for rs2077606 among
all invasive cases (OR=1.12, 95% CI: 1.08-1.16), P=7.8×10−9) and invasive serous cases
(OR=1.15, 95% CI: 1.12-1.19, P=3.9×10−10). These SNPs were chosen for genotyping in
COGS because they had shown evidence of association as modifiers of EOC risk in BRCA1
gene mutation carriers by the Consortium of Investigators of Modifiers of BRCA1/2
(CIMBA)16. Several imputed SNPs in strong LD (r2>0.90) were more strongly associated
with risk than their highly correlated genotyped SNPs (Supplementary Table S2). This risk-
associated region at 17q21.31 is distinct from a previously reported ovarian cancer
susceptibility locus at 17q2117; neither the genotyped or imputed SNPs we report here are
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tstrongly correlated (maximum r2= 0.01) with SNPs from the 17q21 locus (spanning
46.2-46.5 MB, build 37).
Genotype clustering was poor for rs2077606, but clustering was good for its correlated SNP,
rs12942666 (r2=0.99), and so results for this SNP are presented instead (Supplementary Fig.
S2; Table 1). Subgroup analysis revealed marginal evidence of association for rs12942666
with endometrioid (P=0.04), but not mucinous or clear cell EOC subtypes (Table 1), and
results were consistent across studies (Supplementary Fig. S4). Rs12942666 is correlated
with the top-ranked miRSNP, rs1052587 (r2=0.76) (Fig. 1). To evaluate whether
associations observed for rs12942666 and rs1052587 represented independent signals,
stepwise logistic regression was used; only rs12942666 was retained in the model. This
suggests that the cluster which includes rs12942666 is driving the association with EOC risk
that was initially identified through the candidate miRSNPs.
Functional and molecular analyses
To evaluate functional evidence for candidate genes, risk-associated SNPs, and regulatory
regions at 17q21.31, we examined a one megabase region centered on rs12942666 using a
combination of locus specific and genome-wide assays and in silico analyses of publicly
available datasets, including The Cancer Genome Atlas (TCGA) Project18 (see Methods).
Rs12942666 and many of its correlated SNPs lie within introns of Rho GTPase activating
protein 27 (ARHGAP27) or its neighboring gene, pleckstrin homology domain containing,
family M (with RUN domain) member 1 (PLEKHM1) (Supplementary Table S2). There are
another 15 known protein-coding genes within the region: KIF18B, C1QL1, DCAKD,
NMT1, PLCD3, ABCB4, HEXIM1, HEXIM2, FMNL1, C17orf46, MAP3K14, C17orf69,
CRHR1, IMP5, and MAPT (Fig. 2a).
To evaluate the likelihood that one or more genes within this region represent target
susceptibility gene(s), we first analyzed expression, copy number variation, and methylation
involving these genes in EOC tissues and cell lines (Fig. 2b-g; Supplementary Tables S3 and
S4). Most genes showed significantly higher expression (P<10−4) in EOC cell lines versus
normal ovarian cancer-precursor tissues (OCPTs); ARHGAP27 showed the most
pronounced difference in gene expression between cancer and normal cells (P=10−16) (Fig.
2b and Supplementary Table S3). For nine genes, we also found overexpression in primary
high-grade serous (HGS) EOC tumors versus normal ovarian tissue in at least one of two
publicly available datasets, The Cancer Genome Atlas (TCGA) of 568 tumors 18and/or the
Gene Expression Omnibus (GEO) series GSE18520 dataset consisting of 53 tumors19 (Fig.
2c and Supplementary Table S3). Analysis of DNA copy number variation in TCGA
revealed frequent loss of heterozygosity in this region rather than gains (Supplementary Fig.
5a-b; Supplementary Methods). We observed significant hypomethylation (P<0.01) in
ovarian tumors compared to normal tissue for DCAKD, PLCD3, ACBD4, FMNL1, and
PLEKHM1 (Fig. 2d and Supplementary Table S4), which is consistent with the
overexpression observed for DCAKD, PLCD3, and FMNL1. Taken together, these data
suggest that the mechanism underlying overexpression may be epigenetic rather than based
on copy number alterations.
We evaluated associations between genotypes for the top risk SNP rs12942666 (or a
tagSNP) and expression of all genes in the region (expression quantitative trait locus (eQTL)
analysis) in normal OCPTs, lymphoblastoid cell lines (LCLs), and primary tumors from
TCGA. We observed significant eQTL associations (P<0.05) in normal OCPTs only for
ARHGAP27 (P=0.04) (Fig. 2e; Supplementary Table S3). Because rs12942666 was not
genotyped in tissues analyzed in TCGA, we used data for its correlated SNP rs2077606
(r2=0.99) to evaluate eQTLs in tumor tissues. Rs2077606 genotypes were strongly
associated with PLEKHM1 expression in primary HGS-EOCs (P=1×10−4) (Fig. 2f;
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tSupplementary Table S3). We also detected associations between rs12942666 (and
rs2077606) genotypes and methylation for PLEKHM1 and CRHR1 in primary tumors
(P=0.020 and 0.001, respectively) using methylation quantitative trait locus (mQTL)
analyses (Fig. 2g; Supplementary Table S4). Finally, the Catalogue of Somatic Mutations in
Cancer (COSMIC) database 20 showed that nine genes in the region, including PLEKHM1,
have functionally significant mutations in cancer, although for most genes mutations were
not reported in ovarian carcinomas (Supplementary Table S3).
Taken together, these data suggest that several genes at the 17q21.31 locus may play a role
in EOC development. The risk-associated SNPs we identified fall within non-coding DNA,
suggesting the functional SNP(s) may be located within an enhancer, insulator, or other
regulatory element that regulates expression of one of the candidate genes we evaluated.
One hypothesis emerging from these molecular analyses is that rs12942666 (or a correlated
SNP) mediates regulation of PLEKHM1, a gene implicated in osteopetrosis and
endocytosis 21 and/or ARHGAP27, a gene that may promote carcinogenesis through
dysregulation of Rho/Rac/Cdc42-like GTPases 22. To identify the most likely candidate for
being the causal variant at 17q21.31, we compared the difference between log-likelihoods
generated from un-nested logistic regression models for rs12942666 and each of 198 SNPs
in a 1 MB region featured in Supplementary Table 2. As expected, the log likelihoods were
very similar due to the strong LD; no SNPs emerged as having a likelihood ratio greater than
20 for being the causal variant.
To explore the possible functional significance of rs12942666 and strongly correlated
variants (r2>0.80), we then generated a map of regulatory elements around rs12942666
using ENCODE data and FAIRE-seq analysis of OCPTs (Supplementary Methods). We
observed no evidence of putative regulatory elements coinciding with rs12942666 or
correlated SNPs (Fig. 3a). A map of regulatory elements in the entire 1 MB region can be
seen in Supplementary Fig. 5c-f. We subsequently used in silico tools (ANNOVAR23,
SNPinfo24, and SNPnexus25) to evaluate the putative function of possible causal SNPs
(Supplementary Methods). Of 50 SNPs with possible functional roles, more than 30 reside
in putative transcription factor binding sites (TFBS) within or near PLEKHM1 or
ARHGAP27; 12 SNPs may affect methylation or miRNA binding, and two are non-
synonymous coding variants predicted to be of no functional significance (Supplementary
Table S2).
Since most of the top-ranked 17q21.31 SNPs with putative functions (including two of the
top directly genotyped SNPs, rs2077606 and rs17631303), are predicted to lie in TFBS
(Supplementary Table S2), we used the in silico tool, JASPAR 26 to further examine TFBS
coinciding with these SNPs. Two SNPs scored highly in this analysis (Supplementary Table
S5); the first, rs12946900, lies in a GAGGAA motif and canonical binding site for SPIB, an
Ets family member27. Ets factors have been implicated in the development of ovarian cancer
and other malignancies28, but little evidence supports a specific role for SPIB in EOC
etiology. The second hit was for rs2077606, which lies in an E-box motif CACCTG at the
canonical binding site for ZEB1 (chr. 10p11.2), a zinc-finger E-box binding transcription
factor that represses E-cadherin29,30 and contributes to epithelial-mesenchymal transition in
EOCs 31.
We analyzed expression of SPIB and ZEB1 in primary ovarian cancers using TCGA data;
we found no significant difference in SPIB expression in tumors compared to normal tissues
(Fig. 3bi). In contrast, ZEB1 expression was significantly lower in primary HGS-EOCs
compared to normal tissues (P=0.005) (Fig. 3bii). We validated this finding using qPCR
analysis in 123 EOC and OCPT cell lines (P=8.8 ×10−4) (Fig. 3biii). Since rs2077606 lies
within an intron of PLEKHM1, this gene is a candidate target for ZEB1 binding at this site.
Permuth-Wey et al. Page 8
Nat Commun. Author manuscript; available in PMC 2013 July 12.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tOur eQTL analysis also suggests ARHGAP27 is a strong candidate ZEB1 target at this
locus; ARHGAP27 expression is highest in OCPT cell lines carrying the minor allele of
rs2077606 (P=0.034) (Figure 3ci). Although we observed no eQTL associations between
rs2077606 and ZEB1 expression in LCLs (Figure 3cii), we found evidence of eQTL
between rs2077606 and ZEB1 expression in HGS-EOCs (P=0.045) (Figure 3ciii). ZEB1
binding at the site of the common allele is predicted to repress gene expression while loss of
ZEB1 binding conferred by the minor allele may enable expression of ARHGAP27,
consistent with the eQTL association in OCPTs (Fig. 3ci). Although this data supports a
repressor role for ZEB1 in EOC development and suggests ARHGAP27 may be a functional
target of rs2077606 (or a correlated SNP) in OCPTs through trans-regulatory interactions
with ZEB1, it is important to investigate additional hypotheses as we continue to narrow
down the list of target susceptibility genes, SNPs, and regulatory mechanisms that contribute
to EOC susceptibility at this locus.
Discussion
The present study represents the largest, most comprehensive investigation of the
association between putative miRSNPs in the 3′ untranslated region and cancer risk. This
and the systematic follow-up to evaluate associations with EOC risk for non-miRSNPs in
the region identified 17q21.31 as a new susceptibility locus for EOC. Although the
miRSNPs identified here may have some biological significance, our findings suggest that
other types of variants in non-coding DNA, especially non-miRSNPs at the 17q21.31 locus,
are stronger contributors to EOC risk. It is possible, however, that highly significant
miRSNPs exist that were not identified in our study because a) they were not pre-selected
for evaluation (i.e. they do not reside in a binding site involving miRNAs or genes with
known relevance to EOC, or they reside in regions other than the 3′UTR3,4) and/or b) they
were very rare and could not be designed or detected with our genotyping platform and
sample size, respectively. Despite these limitations, the homogeneity between studies of
varying designs and populations in the OCAC and the genome-wide levels of statistical
significance imply that all detected associations are robust. Furthermore, molecular
correlative analyses of genes within the region suggest that cis-acting genetic variants
influencing non-coding DNA regulatory elements, miRNAs, and/or methylation underlie
disease susceptibility at the 17q21.31 locus. Finally, these studies point to a subset of
candidate genes (i.e. PLEKHM1, ARHGAP27) and transcription factors (i.e. ZEB1) that
may influence EOC initiation and development.
This novel locus is one of eleven loci now identified that contains common genetic variants
conferring low penetrance susceptibility to EOC in the general population 17,32,33,34.
Genetic variants at several of these loci influence risks of more than one cancer type,
suggesting that several cancers may share common mechanisms. For example, alleles at
5p15.33 and 19p13.1 are associated with estrogen-receptor-negative breast cancer and
serous EOC susceptibility 32,35, and variants at 8q24 are associated with risk of EOC and
other cancers 17,36. Genetic variation at 17q21.31 is also associated with frontotemporal
dementia-spectrum disorders, Parkinson's disease, developmental delay, and alopecia 37-42.
Through COGS, the CIMBA also recently identified 17q21.31 variants as modifying EOC
risk in BRCA1 and BRCA2 carriers (P<10−8 in BRCA1/2 combined)16. In particular,
rs17631303, which is perfectly correlated with rs2077606 and rs12942666, was among the
top-ranking SNPs detected by CIMBA16. Consistent with our findings, CIMBA also provide
data that suggests EOC risk is associated with altered expression of one or more genes in the
17q21.31 region16. Thus, results from this large-scale collaboration support a role for this
locus in both BRCA1/2 and non-BRCA1/2 mediated EOC development. Before these
findings can be integrated with variants from other confirmed loci and non-genetic factors to
predict women at greatest risk of developing EOC and provide options for medical
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tmanagement of these risks, continued efforts will be needed to fine map the 17q21.31 region
and to fully characterize the functional and mechanistic effects of potential causal SNPs in
disease etiology and development.
Methods
Study population
Forty-three individual OCAC studies contributed samples and data to the COGS initiative.
Nine of the 43 participating studies were case-only (GRR, HSK, LAX, ORE, PVD, RMH,
SOC, SRO, UKR); cases from these studies were pooled with case-control studies from the
same geographic region. The two national Australian case-control studies were combined
into a single study to create 34 case-control sets. Details regarding the 43 participating
OCAC studies are summarized in Supplementary Table S1. Briefly, cases were women
diagnosed with histologically confirmed primary EOC (invasive or low malignant potential),
fallopian tube cancer, or primary peritoneal cancer ascertained from population- and
hospital-based studies and cancer registries. The majority of OCAC cases (>90%) do not
have a family history of ovarian or breast cancer in a first-degree relative, and most have not
been tested for BRCA1/2 mutations as part of their parent study. Controls were women
without a current or prior history of ovarian cancer with at least one ovary intact at the
reference date. All studies had data on disease status, age at diagnosis/interview, self-
reported racial group, and histologic subtype. Most studies frequency-matched cases and
controls on age-group and race.
Selection of Candidate Genes and SNPs
To increase the likelihood of identifying miRSNPs with biological relevance to EOC, we
reviewed published literature and consulted public databases to generate two lists of
candidate genes: 1) 55 miRNAs reported to be deregulated in EOC tumors compared to
normal tissue in at least one study 43-46, and 2) 665 genes implicated in the pathogenesis of
EOC through gene expression analyses 47,48, somatic mutations 49, or genetic association
studies 50,51. Many genes were identified through the Gene Prospector database51, a web-
based application that selects and prioritizes potential disease-related genes using a highly
curated, up-to-date database of genetic association studies.
Using each candidate gene list as input, we identified putative sites of miRNA:mRNA
binding with the computational prediction algorithms TargetScan version 5.1 10,11 and
PicTar 12,13 and Supplementary Methods). Each algorithm generated start and end
coordinates for regions of miRNA binding, and database SNP (dbSNP)52 version 129 was
mined to identify SNPs falling within the designated binding regions. Of 3,246 unique
miRSNPs that were identified, 1102 obtained adequate design scores using Illumina's Assay
Design Tool. The majority (n=1085, 98.5%) of the 1102 SNPs resided in predicted sites of
miRNA binding (and therefore represent miRSNPs), while the remainder (n=17) are
tagSNPs (r2 > 0.80) for miRSNPs that were not designable or had poor to moderate design
scores. Ninety nine of the 1102 SNPs failed during custom assay development, leaving a
total of 1,003 SNPs that were designed and genotyped.
Genotyping and QC
The candidate miRSNPs selected for the current investigation were genotyped using a
custom Illumina Infinium iSelect Array as part of the international Collaborative
Oncological Gene-environment Study (COGS), an effort to evaluate 211,155 genetic
variants for association with the risk of ovarian, breast, and prostate cancer. Samples and
data were included from several consortia, including OCAC, the Breast Cancer Association
Consortium (BCAC), the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA),
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tand the Prostate Cancer Association Group to Investigate Cancer- Associated Alterations in
the Genome (PRACTICAL). Although one of the primary goals of COGS was to replicate
and fine-map findings from pooled genome-wide association studies (GWAS) from each
consortia, this effort also aimed to genotype candidate SNPs of interest (such as the
miRSNPs). The genotyping and QC process has been described recently in our report of
OCAC's pooled GWAS findings34. Briefly, COGS genotyping was conducted at six centers,
two of which were used for OCAC samples: McGill University and Génome Québec
Innovation Centre (Montréal, Canada) (n=19,806) and Mayo Clinic Medical Genomics
Facility (n=27,824). Each 96-well plate contained 250ng genomic DNA (or 500 ng whole
genome-amplified DNA). Raw intensity data files were sent to the COGS data coordination
center at the University of Cambridge for genotype calling and QC using the GenCall
algorithm.
Sample QC—One thousand two hundred and seventy three OCAC samples were
genotyped in duplicate. Genotypes were discordant for greater than 40 percent of SNPs for
22 pairs. For the remaining 1,251 pairs, concordance was greater than 99.6 percent. In
addition we identified 245 pairs of samples that were unexpected genotypic duplicates. Of
these, 137 were phenotypic duplicates and judged to be from the same individual. We used
identity-by-state to identify 618 pairs of first-degree relatives. Samples were excluded
according to the following criteria: 1) 1,133 samples with a conversion rate (the proportion
of SNPs successfully called per sample) of less than 95 percent; 2) 169 samples with
heterozygosity >5 standard deviations from the intercontinental ancestry specific mean
heterozygosity; 3) 65 samples with ambiguous sex; 4) 269 samples with the lowest call rate
from a first-degree relative pair 5) 1,686 samples that were either duplicate samples that
were non-concordant for genotype or genotypic duplicates that were not concordant for
phenotype. A total of 44,308 eligible subjects including 18,174 cases and 26,134 controls
were available for analysis.
SNP QC—The process of SNP selection by the participating consortia has been
summarized previously34. In total, 211,155 SNP assays were successfully designed,
including 23,239 SNPs nominated by OCAC. Overall, 94.5% of OCAC-nominated SNPs
passed QC. SNPs were excluded if: (1) the call rate was less than 95% with MAF > 5% or
less than 99% with MAF < 5% (n=5,201); (2) they were monomorphic upon clustering
(n=2,587); (3) p values of HWE in controls were less than 10−7 (n=2,914); (4) there was
greater than 2% discordance in duplicate pairs (n=22); (5) no genotypes were called
(n=1,311). Of 1,003 candidate miRSNPs genotyped, 767 passed QC criteria and were
available for analysis; the majority of miRSNPs that were excluded were monomorphic
(n=158, 67%). Genotype intensity cluster plots were visually inspected for the most strongly
associated SNPs.
Population stratification
HapMap DNA samples for European (CEU, n=60), African (YRI, n=53) and Asian (JPT
+CHB, n=88) populations were also genotyped using the COGS iSelect. We used the
program LAMP 53 to estimate intercontinental ancestry based on the HapMap (release no.
23) genotype frequency data for these three populations. Eligible subjects with greater than
90 percent European ancestry were defined as European (n=39,773) and those with greater
than 80 percent Asian or African ancestry were defined as Asian (n=2,382) or African
respectively (n=387). All other subjects were defined as being of mixed ancestry (n=1,766).
We then used a set of 37,000 unlinked markers to perform principal components analysis
within each major population subgroup. To enable this analysis on very large sample sizes
we used an in-house program written in C++ using the Intel MKL libraries for eigenvectors
(available at http://ccge.medschl.cam.ac.uk/software/).
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tTests of association
We used unconditional logistic regression treating the number of minor alleles carried as an
ordinal variable (log-additive model) to evaluate the association between each SNP and
EOC risk. Separate analyses were carried out for each ancestry group. The model for
European subjects was adjusted for population substructure by including the first 5
eigenvalues from the principal components analysis. African- and Asian- ancestry-specific
estimates were obtained after adjustment for the first two components representing each
respective ancestry. Due to the heterogeneous nature of EOC, subgroup analysis was
conducted to estimate genotype-specific odds ratios for serous carcinomas (the most
predominant histologic subtype) and the three other main histological subtypes of EOC:
endometrioid, mucinous, and clear cell. Separate analyses were also carried out for each
study site, and site-specific ORs were combined using a fixed-effect meta-analysis. The I2
test of heterogeneity was estimated to quantify the proportion of total variation due to
heterogeneity across studies, and the heterogeneity of odds ratios between studies was tested
with Cochran's Q statistic. The R statistical package ‘r-meta’ was used to generate forest
plots. Statistical analysis was conducted in PLINK54.
Imputation of genotypes at 17q21.31
To increase genomic coverage, we imputed genotype data for the 17q21.31 region (chr17:
40,099,001-44,900,000, human genome build 37) with IMPUTE2.2 55 using phase 1
haplotype data from the January 2012 release of the 1000 genome project data 15. For each
imputed genotype the expected number of minor alleles carried was estimated (as weights).
IMPUTE provides estimated allele dosage for SNPs that were not genotyped and for
samples with missing data for directly genotyped SNPs. Imputation accuracy was estimated
using an r2quality metric. We excluded imputed SNPs from analysis where the estimated
accuracy of imputation was low (r2<0.3).
Functional studies and in silico analysis of publicly available datasets
We performed the following assays for each gene in the one megabase region centered on
the most significant SNP at the 17q21.31 locus (see Supplementary Methods): gene
expression analysis in EOC cell lines (n=51) compared to normal cell lines from ovarian
cancer precursor tissues (OCPTs)56, including ovarian surface epithelial cells (OSECs) and
fallopian tube secretory epithelial cells (FTSECs) (n=73), and CpG island methylation
analysis in high grade serous ovarian cancer (HGS-EOC) tissues (n=106) and normal tissues
(n=7). Genes in the region were also evaluated in silico by mining publicly available
molecular data generated for primary EOCs and other cancer types, including The Cancer
Genome Atlas (TCGA) analysis of 568 HGS EOCs18, the Gene Expression Omnibus series
GSE18520 dataset of 53 HGS EOCs 19, and the Catalogue Of Somatic Mutations In Cancer
(COSMIC) database20.
We used these data to 1) compare gene expression between a) EOC cell lines and normal
cell lines and b) tumor tissue and normal tissue from TCGA, 2) compare gene methylation
status in HGS-EOCs and normal tissue, 3) conduct gene expression quantitative trait locus
(eQTL) analyses to evaluate genotype-gene expression associations in normal OCPTs,
lymphoblastoid cells, and HGS-EOCs, and 4) conduct methylation quantitative trait locus
(mQTL) analyses in HGS-EOCs to evaluate genotype-gene methylation associations. Data
from ENCyclopedia Of DNA Elements (ENCODE) 57 were used to evaluate the overlap
between regulatory elements in non-coding regions and risk-associated SNPs. ENCODE
describes regulatory DNA elements (e.g. enhancers, insulators and promotors) and non-
coding RNAs (e.g. miRNAs, long non-coding and piwi-interacting RNAs) that may be
targets for susceptibility alleles. However, ENCODE does not include data for EOC
associated tissues, and activity of such regulatory elements often varies in a tissue specific
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tmanner 57,58. Therefore, we profiled the spectrum of non-coding regulatory elements in
OSECs and FTSECs using a combination of formaldehyde assisted isolation of regulatory
elements sequencing (FAIRE-seq) and RNA sequencing (RNA-seq) (Supplementary
Methods).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Regional association plot for genotyped and imputed SNPs at 17q21.31
The middle portion of the plot contains the region of the inversion polymorphism (ch 17:
43,624,578-44,525,051, hg build 37), with the four blue dots representing the candidate
miRSNPs (rs4640231, rs1052587, and rs17574361) and the tagSNP, rs916793. rs1052587 in
the 3′UTR of MAPT has the strongest signal (P=4.6×10−8) among the miRSNPs. The
cluster on the left side of the plot (around 43.5 MB) contains highly correlated SNPs
(r2=0.99), including three directly genotyped intronic SNPs, rs2077606 and rs17631303 in
PLEKHM1 (P=3.9 × 10−10 and P=4.7 × 10−10, respectively), and rs12942666 in
ARHGAP27 (P=1.0 × 10−9). The linkage disequilibrium between each plotted SNP and the
top-ranked SNP in the region with the best clustering, rs12942666, is depicted by the color
scheme; the deeper the color red, the stronger the correlation between the plotted SNP and
rs12942666. The top miRSNP, rs1052587, is moderately correlated (r2=0.76) with
rs2077606, rs17631303, and rs12942666 in our study population. (n=8,371 invasive serous
cases and n= 23,491 controls, of European ancestry).
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tFigure 2. Expression and methylation analyses at the 17q21.31 ovarian cancer susceptibility
locus
(a) Genomic map and LD structure. The location and approximate size of 17 known protein
coding genes (grey) and one microRNA (blue) in the region are shown relative to the
location of rs12942666. Orange indicates the location of the inversion polymorphism, and
green indicates the region outside the inversion.
(b) Gene expression (EOC and normal cell lines). Gene expression analysis in Epithelial
Ovarian Cancer (EOC) cell lines (T; n=51) compared to normal ovarian surface epithelial
cells (OSECs) and fallopian tube secretory epithelial cells (FTSEC) (N; n=73) (* p<0.05,
**p<0.01, ***p<0.001).
(c) Gene expression (Primary EOCs and Normal Tissue). Boxplots of The Cancer Genome
Atlas (TCGA) Affymetrix U133A-array based gene expression in primary high-grade serous
ovarian tumors (T; n=568) and normal fallopian tube tissues (N; n=8). Where data were not
available in TCGA, gene expression data from the Gene Expression Omnibus series
GSE18520 dataset containing 53 high-grade serous tumors and 10 normal ovarian tissues
are shown (indicated by a red asterisk).
(d) Methylation (Primary Tumors and Normal Tissue). Methylation analysis of 106 high-
grade serous ovarian tumors compared to normal ovarian tissues (n=7). Methylation data
were generated for CpG site(s) associated with each gene using the Illumina 450
methylation array. Pairwise analysis of methylation for an individual CpG for each gene is
based on the CpG with most significant inverse relationship to gene expression (i.e. cis
negative), for a subset of 43 tumors having available gene expression data. Statistically
significant cis-negative probes are indicated by a red open circle.
(e) Expression quantitative trait locus (eQTL) analysis (OSECs/FTSECs). eQTL analysis
comparing expression for each gene to genotype for the most statistically significant SNP at
17q21.31 (rs12942666), for 73 normal OSEC/FTSEC lines. Data are presented as box plots
comparing expression levels in cases carrying rare homozygotes/heterozygotes, with cases
homozygous for the common allele.
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t(f) Expression quantitative trait locus (eQTL) analysis (Primary EOCs). eQTL analysis
comparing expression for each gene to genotype using level 3 gene expression profiling data
from Agilent 244K custom arrays and level 2 genotype data from the Illumina 1M-Duo
BeadChip for 568 high-grade serous ovarian cancer patients from TCGA. In all panels *
p<0.05, **p<0.01, *** p<0.001. Grey X's indicate data not available. Here, genotype data
for rs2077606 is used (rather than rs12942666) because rs12942666 was not genotyped in
the TCGA dataset.
(g) Methylation quantitative trait locus (mQTL) analysis (Primary EOCs). mQTL analysis
showing methylation status in 227 high-grade serous EOCs relative to rs12942666 genotype.
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tFigure 3. eQTL associations between the rs2077606 susceptibility SNP at 17q21
(a) Analysis of the chromatin landscape at ARHGAP27 and PLEKHM1 in normal ovarian
surface epithelial and fallopian tube secretory epithelial cells (OSECs/FTSECs) by
formaldehyde assisted isolation of regulatory elements sequencing (FAIRE-seq). Alignment
with ENCODE FAIRE-seq tracks (shown) and ChIP-seq tracks (not shown) from non-EOC
related cell lines reveals open chromatin peaks corresponding to (a) promoters (b) CTCF
insulator binding sites and (c) H3K4me3 signals, suggestive of a dynamic regulatory region.
An H3K4me3 signal at a coding ARHGAP27 mRNA variant (c) located between the genes
is highly pronounced in OSEC/FTSEC, suggesting tissue-specific expression and function.
Several of the top-ranking SNPs fall within transcription factor binding sites (TFFS)
(Supplementary Table S2). rs12942666 did not coincide with TFBS, but tightly linked
SNPs, rs12946900 and rs2077606 fell within predicted binding sites for SPIB and ZEB1,
respectively.
(b) We analyzed the expression of SPIB and ZEB1 in primary high-grade serous tumors
from TCGA and found (i) no significant change in SPIB expression but (ii) significant
down-regulation of ZEB1 in tumors compared to normal tissues. (iii) QPCR analysis of
ZEB1 expression in 73 OCPT and 50 EOC cell lines replicated the finding that ZEB1
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texpression is lower in cancer cell lines compared to normal precursor tissues. (c) eQTL
analysis in OSECs/FTSECs for different alleles of rs2077606. There was a (i) significant
eQTL for ARHGAP27, with the minor (A) allele being associated with increased
ARHGAP27 expression (P=0.034), (ii) no evidence of an association between rs2077606
genotypes and ARHGAP27 expression in lymphoblastoid cell lines suggesting this
association may be tissue-specific. (iii) We observed a borderline significant eQTL
association between ZEB1 mRNA and rs2077606 in tumors from TCGA, with the minor
risk allele also associated with lower expression.
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